Clinical Trial Search

Primary: Maximum Tolerated Dose (MTD) When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma…

Primary: Participants With Objective Response — 7 Participants

Primary: Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score (Changes From Baseline to 14 Months) — 0.8; 0.8; 1.5; 3.2 units on a scale

Primary: Phase I Cohort A: Maximum Tolerated AZD0530 Daily Dose Used in Combination With Daily Oral Anastrozole — 1; 175 mg/day oral dose

Primary: Patient Reported Measures From Interpersonal Processes of Care Survey — 73; 78; 77 score on a scale

Primary: Change in WIQ Distance Subscore — 22.7; -7.2 Scale units

Primary: Cycloplegic Refraction Change in SER — -0.93; -0.38 Diopters (D)

Primary: Number of Participants With Adverse Events — 6; 4; 3; 6 Participants

Primary: Number of Participants Who Attended Initial Assessment Appointment — 140; 134 Participants

Primary: Number of Participants Reporting Product Tolerability Based on Evaluator Global Assessment Scores — 47; 44; 0; 0 Participants

Primary: Evaluate Changes in Bleeding Duration Among Women Initiating the Copper T380 IUD During the 90 Days Prior to Initiation Compared to Two 90 Periods After IUD Insertion…

Primary: Mean Change in Cerebral Blood Flow as Measured by Magnetic Resonance Imaging (MRI) — 0.621528; 0.6447692; 0.654822667; 0.579838667 ml/110g/min

Primary: Number of Participants With Decrease in Knee Valgus Measurement — 307; 216 Participants

Primary: Procedure Preference and Acceptability Questionnaire and Visual Analog Scale — 7.2; 8.5; -1.3; 16.2 Units on a scale

Primary: Assessment of Spondyloarthritis International Society Criteria (ASAS) 20 Response From Week 104 to Week 260 — 71.4; 80.0; 78.6; 73.0 % of responders